BioNTech to develop mRNA malaria shot

Monday, 26. July 2021 16:25

BioNTech SE unveiled on Monday it will use parts of the profits obtained from the sales of the COVID-19 vaccine, which it developed with Pfizer Inc., to develop an mRNA shot against malaria.

The company issued a statement explaining that the "Malaria project's" second goal is to develop a network of manufacturing facilities throughout Africa to ensure "sustainable vaccine production and supply solutions."

The German pharmaceutical company also announced it will start a clinical trial of its tuberculosis vaccine candidate in 2022.

The company's shares were up 3.7% at 10:23 am ET, selling for $292.44.

Related Links: BioNTech SE
Breaking the News / BU